Antibe Therapeutics (TSX:ATE) EBIT per Share : C$-0.35 (TTM As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Antibe Therapeutics EBIT per Share?

Antibe Therapeutics's EBIT per Share for the three months ended in Dec. 2023 was C$-0.08. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.35.

During the past 3 years, the average EBIT per Share Growth Rate was 14.80% per year. During the past 5 years, the average EBIT per Share Growth Rate was 2.60% per year. During the past 10 years, the average EBIT per Share Growth Rate was 3.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Antibe Therapeutics's EBIT per Share or its related term are showing as below:

TSX:ATE' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -48.8 Med: -4.1 Max: 28.3
Current: 14.8

During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of Antibe Therapeutics was 28.30% per year. The lowest was -48.80% per year. And the median was -4.10% per year.

TSX:ATE's 3-Year EBIT Growth Rate is ranked better than
65.06% of 1305 companies
in the Biotechnology industry
Industry Median: 3.6 vs TSX:ATE: 14.80

Antibe Therapeutics's EBIT for the three months ended in Dec. 2023 was C$-4.21 Mil.

Antibe Therapeutics EBIT per Share Historical Data

The historical data trend for Antibe Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antibe Therapeutics EBIT per Share Chart

Antibe Therapeutics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EBIT per Share

Get a 7-Day Free Trial

-0.57

-0.68

-0.64

-0.50

-0.37

Antibe Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															-0.08	-0.06	-0.11	-0.10	-0.08

Antibe Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Antibe Therapeutics's EBIT per Share for the fiscal year that ended in Mar. 2023 is calculated as

	EBIT per Share		(A: Mar. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-19.283	/	52.286
=	-0.37

Antibe Therapeutics's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-4.211	/	52.651
=	-0.08

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.35

Antibe Therapeutics (TSX:ATE) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Antibe Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Antibe Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Antibe Therapeutics (TSX:ATE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antibe Therapeutics Inc (TSX:ATE) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

ATBPF:USA

Address

15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2

Website

https://www.antibethera.com

Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.

Executives

Daniel Marcel Legault	Senior Officer
Alain Wilson	Senior Officer
John Lawrence Wallace	Director, Director or Senior Officer of 10% Security Holder, Senior Officer
Nicolas Bourgeois	Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Scott Wilson Curtis	Senior Officer

Antibe Therapeutics (TSX:ATE) Headlines

No Headlines